ISPOR - HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study

Full Text

HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study

Abstract

Authors

H. Harrington S. Madueke A.V. Vasilyeva J. Micallef

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now